Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context. The widespread adoption of PSMA PET imaging has ...
FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a ...
Dr. Evan Wu presents William, a 76-year-old Black man and former smoker (25 pack-year history, quit 15 years ago) who ...
A data monitoring committee recommended stopping FLASH2, a randomized double-blind placebo-controlled confirmatory phase 3 ...
Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...
The rapid evolution of advanced therapies like cell and gene therapies is reshaping the oncology landscape and challenging ...
Dr. Alexander B. Olawaiye speaks on how the ROSELLA trial shows relacorilant plus nab-paclitaxel improves survival in ...
Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, explores the safety and tolerability of ...
How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to ...
When comprehensive tissue next-generation sequencing (NGS) fails, liquid biopsy should be the reflex strategy, especially in ...
Dr Dulmage highlights that one of the most frequently overlooked early warning signs of clinically significant dermatologic ...
The FDA granted regenerative medicine advanced therapy (RMAT) designation to Orca-Q, a second-generation investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results